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Previous studies showed that the accumulation of advanced glycation end products (AGEs) induce cardiomyocyte
apoptoisis, leading to heart dysfunction. However, the effect of AGEs on another cell death pathway, autophagy, in
cardiomyocytes remains unknown.
Methods: Rat neonate cardiomyocytes were cultured and treated with AGEs at different concentration. Two classic
autophagy markers, microtubule-associated protein 1 light chain 3 (LC3) and Beclin-1, were detected by western
blot assay. The inhibition of RAGE and phosphatidylinositol 3-phosphate kinase (PI3K)/Akt/mTOR pathway were
applied to cells, respectively.
Results: AGEs administration enhanced the expression of Beclin-1 and LC3 II in cardiomyocytes, increased the number
of autophagic vacuoles and impaired the cell viability in dose-dependant manners. Also, AGEs inhibited the PI3K/Akt/
mTOR pathway via RAGE. Inhibition of RAGE with RAGE antibody reduced expression of Beclin-1 and LC3 II/I and
inhibited the cellular autophagy, accompanied by the reactivation of PI3K/Akt/mTOR pathway in cultured cells. Notably,
the presence of inhibition of PI3K/Akt/mTOR pathway abolished the protective effect of RAGE inhibition on
cardiomyocytes.
Conclusion: This study provides evidence that AGEs induces cardiomyocyte autophagy by, at least in part, inhibiting
the PI3K/Akt/mTOR pathway via RAGE.
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Advanced glycation endproducts (AGEs) are a group of
heterogeneous compounds accumulated in diabetes due to
factors including increased reactive carbohydrate substrate
availability, oxidative condition favoring glycation and im-
paired detoxification [1]. AGEs form and accumulate in
aging, renal failure, inflammation and especially diabetes
mellitus (DM) [2]. Different cell membrane proteins have
been shown to bind AGE and the best characterized recep-
tor for AGE has been named receptors for advanced glyca-
tion end products (RAGE) [3]. The interaction between
AGEs and RAGE participates in a variety of physiopatho-
logical process, including inflammation, carcinogenesis,
atherosclerosis, nephropathy and neurodegeneration.* Correspondence: beckhxw007@gmail.com
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unless otherwise stated.In diabetes mellitus, AGE/RAGE interaction contributes
to the development of diabetic complications, including
diabetic cardiomyopathy [4]. As one of the major compli-
cations of DM, diabetic cardiomyopathy is manifested by
progressive heart failure and a poor prognosis in DM pa-
tients [5,6]. Previous studies had documented that the
AGEs accumulation induces cardiomocyte apoptosis, lead-
ing to caricardiomocyte loss, is one of major mechanism
leading to the development of heart dysfunction in dia-
betic cardiomyopathy [7].
Apoptosis is the type I programmed cell death pathway.
Besides apoptosis, it also exists another type II pathway in
mammal cells, namely, autophagy [8]. As a regulator of
programmed cell death in mammals, autophagy is triggered
by a variety of physiopathological stimuli, e.g. starvation,
hypoxia, intracellular stress, hormones, ischemia and me-
tabolism disorders [9]. Autophagy plays an essential role
for mammal cell growth, survival, differentiation and. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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detrimental to cell fate, causing massive cell death and even-
tually leading to the function impairment in vivo [11-13].
Accumulating evidence indicate that autophagy is in-
volved in the development of cardiovascular diseases.
Autophagy is upregulated in almost all cardiac patho-
logical states, exerting both protective and detrimental
functions dependant on the extent of autogphagy [14].
Recent studies revealed massive presence of autophagic
death in dead and dying cardiomyocytes in the failing
hearts, including dilated cardiomyopathy, valvular heart
diasese, hypertensive heart disease and chronic ischemia
[15-18]. Notably, the presence of autophagic cardiomyo-
cyte death in failing heart was more prevalent than that
of apoptotic cells, suggesting an important role of au-
tophagy in the cardiomocyte loss and heart function de-
terioration [19]. Excessive cardiac autophagy has been
proposed as a maladaptive response that contributes to
heart failure progression [20]. Autophagy may transform
compensatory cardiac hypertrophy to pump failure. Di-
minished autophagy is reported to limits cardiac dys-
function in type 1 diabetes [21].
The phosphatidylinositol 3-phosphate kinase (PI3K) /Akt/
mTOR signaling pathway is a well-known pathway in-
volved in the regulation of autophagy in mammal cells
[22]. A recent study showed that AGEs can inactivate
Akt in rat vascular smooth muscle cells [23]. However,
the effect of AGEs on cardiomocyte autophagy remains
unknown. In this study, we sought to explore: 1. the role
of AGEs in inducing cardiomocyte autophagy; 2. the
possible signal pathway involved in the effect of AGEs
on cardiomyocyte autophagy.Methods
AGE preparation
AGE-bovine serum albumin (AGE-BSA) were prepared by
incubating BSA (Sigma, St. Louis, MO) with 500 mmol/L
of d-glucose under aerobic conditions for 10 weeks at 37°C
in the presence of protease inhibitors and antibiotics based
on published methods [24].Rat neonatal cardiomyocyte culture
For isolation and culture of Wistar rat neonatal cardio-
myocytes, whole hearts from neonate rats (age less than
3 days) were isolated, minced and rinsed in hood. Five
to six cycles of digestion using collagenase were per-
formed. At the end of each cycle, the suspension was
centrifuged and the supernatant collected, pooled, cen-
trifuged and resuspended in the cardiac medium con-
taining DMEM and M199 (volume ratio: 4:1). The
medium was replaced every 48 h until cardiomyocytes
reached >80% confluence for use.Cell treatment
Neonatal cardiomyocyte were treated with AGEs (10 mg/L,
25 mg/L, 50 mg/L and 100 mg/L for 48 hours). Also, anti-
RAGE antibody (10 μg/ml, Abcam, USA) was used to
block the binding of AGEs to RAGE. An mTOR inhibitor,
Rapamycin (100 nM, Invitrogen, USA) was added to cul-
tured cells to block the PI3K/Akt/mTOR in this study.
Western blot assay
Cells were collected and lysed. The protein contents were
determined. Samples were resolved by SDS-PAGE and
electroblotted onto a polyvinylidene difluoride membrane.
Afterward, membranes were incubated respectively with
an anti-Belcin1(1:1000 dilution, Abcam, USA), anti-LC3
(1:1000 dilution, Abcam, USA), anti-phosphorylated PI3K
(p-PI3K, 1:1000 dilution, Abcam, USA) and total PI3K (t-
PI3K, 1:1000 dilution, Abcam, USA), anti-phosphorylated
Akt (p-Akt, 1:1000 dilution, Millipore, USA) and total Akt
(t-Akt, 1:1000 dilution, Millipore, USA), anti-mTOR
(1:1000 dilution, Millipore, USA) and anti-GAPDH anti-
bodies 1:1000 dilution, Millipore, USA) overnight at 4°C,
followed by incubation with the horseradish peroxidase-
conjugated anti-rabbit IgG for 1 h at room temperature.
The signals were enhanced using a chemiluminescence
system (Amersham Pharmacia Biotech, Buckinghamshire,
England).
Cell viability MTT assay
Cardiomyocytes were plated in microtitre plate at a dens-
ity of 3 × 105 cells/mL. MTT was added to each well with
a final concentration of 0.5 mg/mL, and the plates were
incubated for another 2 h at 37°C and were quantified
spectroscopically at 560 nm using a SpectraMax® 190
spectrophotometer.
GFP-LC3 expression analysis and autophagosome
quantitative analysis
For autophagy detection, 1×103 cardiomyocytes were seeded
into 96-well plates. Cultured cardiomyocytes were trans-
duced with the adenovirus GFP-LC3 (Invitrogen, USA) at a
multiplicity of infection of 60 for 24 h. The number of GFP-
LC3 dots was determined by manual counting in 5 fields,
and nuclear number was evaluated by counting DAPI-
stained nuclei in the same fields using the same magnifica-
tion. The number of GFP-LC3 puncta/cell was evaluated as
the total number of dots divided by the number of nuclei in
each microscopic field.
Electron microscopy
Cardiomyocytes were fixed in 3% paraformaldehyde, 2.5%
glutaraldehyde, and 0.1 m cacodylate buffer (pH 7.4). After
washing with the buffer solution and post-fixation in 1%
OsO4 and 0.1 m cacodylate buffer (pH 7.4), they were
washed with the buffer solution, dehydrated using alcohol
Hou et al. Cardiovascular Diabetology 2014, 13:78 Page 3 of 8
http://www.cardiab.com/content/13/1/78and acetone, and embedded in epoxy resin. Ultrathin sec-
tions were examined under the electron microscope.
Statistic analyses
Data are presented as mean ± S.E.M. Data were analyzed
using a one-way ANOVA followed by the S-N-Keuls post-
hoc analysis. To evaluate the amount of protein expression,
the Raytest TINA software (http://www.raytest.de/service/
raytest_catalog.html) was used for western blotting to cal-
culate the densitometric analysis. The differences in the
relative expressions among different genotypes were com-
pared by using ANOVA analyses. The analyses were per-
formed with the SPSS software (Statistical Package for the
Social Sciences, version 16.0, SPSS Inc, Chicago, IL, USA).
Results
AGEs increase RAGE, Belcin1 and LC3-II expressions
Figure 1 shows the RAGE, LC3 and Beclin-1 protein
expressions after AGEs treatment at different concen-
trations. LC3 shows two bands on western blot assay,
namely, LC3-II and LC3-I (Figure 1a). The relative ex-
pression ratio between LC3-II and LC3-I (LC3-II/LC3-
I) is used to evaluate the extent of autophagy. Our
results showed that the AGEs administration stimu-
lated the expressions of RAGE, Beclin 1 and LC3 II inFigure 1 AGEs affect the expressions of RAGE, Belcin1 and LC3-I and
stimulated the expressions of RAGE (a), LC3 (b) and Beclin 1 (c) in dose-dedose-dependant manners. Quantitative analyses revealed
that the relative expression ratios of RAGE/GAPDH, LC3-
II/LC3-I and Beclin1/GAPDH increased in cardiomyoctye
with AGEs concentrations (Figure 1a-1c).
AGEs treatment induces typical autophagic changes
Double-membrane vacuoles are the typical morpho-
logical changes in autophagy under electron microscopy
observation. Figure 2a shows the typical double-membrane
vacuoles in cultured cardiomyocytes. The presence of
autophagic double-membrane vacuoles was rare in con-
trol cardiomyocytes (Figure 2a). With the increase of
AGEs concentrations, the presence of autophagic vacuoles
became progressively prevalent. For quantitative analyses,
we counted the appearance of double-membrane vacuoles
in 5 random fields for each sample. The mean number of
autophagic vacuoles gradually increased with the con-
centration of AGEs (2.1 ± 0.9 at 10 mg/L; 2.7 ± 0.1
at 25 mg/L; 3.3 ± 0.4 at 50 mg/L;4.5 ± 0.3 at 100 mg/L;
P < 0.001).
The formation of autolysosome in cultured cardio-
myocytes was detected by intra-cellular GFP-LC3 re-
distribution and calculated as the average number of
LC3-labeled puncta per cell (Figure 2b). Compared
with controls, AGEs augmented the average number ofLC3-II expressions in cultured cardiomyocytes. AGEs administration
pendant manners.
Figure 2 The representative figures of double-membrane vacuoles under electron microscopy observation (arrow heads, 2a) and
intra-cellular GFP-LC3 redistribution (green spots, 2b) in cultured cardiomyocytes treated with different AGEs concentration.
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concentrations (2.2 ± 0.13 at 10 mg/L; 2.7 ± 0.20 at
25 mg/L; 4.6 ± 0.13 at 50 mg/L and 7.9 ± 0.19 at100 mg/L, P < 0.001). Collectively, these results suggest
that AGEs induced autophagy in cultured cardiomyo-
cyte in a dose dependant manner.
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We next tested the effects of AGEs exposure on the car-
diomyocyte viability. MTT assay shows that AGEs im-
pair cardiomyocyte viability in a dose-dependant manner
(Figure 3). With the increase of AGEs concentration, the
cell viability decreased progressively and reached a low-
est level at AGEs 100 mg/L.
AGEs inhibits the PI3K/Akt/mTOR pathway via RAGE
Western blot assay shows that the AGEs treatment stimu-
lated the RAGE expression, however, inhibited the PI3K/
Akt/mTOR pathway in cultured cardiomyocytes com-
pared to controls (Figure 4). When RAGE was blocked by
RAGE antibody pretreatment, the PI3K/Akt/mTOR path-
way was re-activated indicated by the increased expression
ratios of p-PI3K/t-PI3K, p-Akt/t-Akt and mTOR/GAPDH
with RAGE blockage. These results suggest AGEs deacti-
vate the PI3K/Akt/mTOR pathway via its receptor RAGE.
Inhibition of AGEs and PI3K/Akt/mTOR pathway on
autophagy level
We next test the role of PI3K/Akt/mTOR pathway in AGEs
induced autophagy in cardiomyocytes by using mTOR in-
hibitor, rapamycin. Figure 4 show that rapamycin dramatic-
ally inhibited the mTOR expression and increased the
Beclin1 and LC3-II expression levels, without affecting the
expression of RAGE, PI3K and Akt. As mentioned above,
RAGE antibody pretreatment activated the PI3K/Akt/
mTOR pathway, and markedly brought down the autoph-
agy marker Belcin1 and LC3-II expressions. However, when
cells were co-treated with rapamycin, the mTOR expres-
sion induced by RAGE antibody was inhibited, accompan-
ied by increased Belcin1 and LC3-II expressions.
We performed the GFP-LC3 assay in cultured cells.
Compared to control cells, rapamycin along increased the
autophagy level indicated by the number of average num-
ber of LC3-labeled puncta per cell (Figure 5). AGEs at
50 mg/L significantly prompted the LC3 translocation,
while the RAGE antibody pretreatment markedly reduced
the formation of autolysosome in cultured cardiomyo-
cytes. Interestingly, when these cells were treated with
rapamycin, the number of LC3-labeled puncta per cell wasFigure 3 The effects of AGEs exposure on the cardiomyocyte viability
dose-dependant manner.increased again (Figure 5). These results provide direct
evidence to support the involvement of RAGE/ PI3K/
Akt/mTOR pathway in AGEs induced autophgy in
cardiomyocytes.
Inhibition of RAGE and PI3K/Akt/mTOR pathway on
cell viability
MTT assay evaluated the cardiomyocyte viability after the
Inhibition of RAGE and PI3K/Akt/mTOR pathway on
Cell viability Figure 6. Compared to control cells, rapamy-
cin along did not significanlty change the cell viability.
RAGE antibody dramatically improved the cell viability in-
duced by AGEs treatment; however, rapamycin addition
to these cells will impair the cell viability.
Discussion
In the present study, we found that AGEs administration
enhanced the expression of Beclin-1 and LC3 in cardio-
myocytes, increased the number of autophagic vacuoles
and more importantly, impaired the cell viability in dose-
dependant manners. Inhibition of RAGE with sRAGE
pretreatment reduced the Beclin-1 and LC3 II expressions,
ameliorated the cardiomyocyte ultra-structure and im-
proved the cell viability to AGEs exposure. Furthermore,
we found that AGEs inhibits the PI3K/Akt/mTOR pathway
via RAGE, while blockage RAGE re-activated PI3K/Akt/
mTOR pathway, however, the addition with PI3K inhibitor
redeuced the cell autophagy and improve the cell viability.
Our data suggest that the AGEs induced cardiomyoctye au-
tophagy, at least in part, via RAGE/PI3K/Akt/mTOR path-
way. As far as we know, this is the first study reporting the
effect of AGEs on autophagy of cardiomyocytes.
Recently the heart function losses induced by excessive
autophagy attract much more attention. Autophagy was re-
ported to be detected in cardiomyocytes from patients with
aortic stenosis and dilated cardiomyopathy [25-28]. Like in
other tissues, autophagy in the heart under baseline condi-
tions is a homeostatic mechanism for maintaining cardio-
myocyte size, global cardiac structure and function.
Autophagy has been observed in both hypertrophied
myocardium [29] and failing myocardium with a variety
of etiology, including dilated cardiomyopathy [30,31]. MTT assay shows that AGEs impair the cardiomyocyte viability in a
Figure 4 The effect of AGEs treatment on RAGE ,PI3K/Akt/mTOR pathway in cultured cardiomyocytes. AGEs treatment stimulated the
RAGE expression, however, inhibited the PI3K/Akt/mTOR pathway in cultured cardiomyocytes compared to controls. RAGE antibody pretreatment
re-activated the PI3K/Akt/mTOR pathway and reduced Beclin1 and LC3-II. Interestingly, the addition mTOR inhibitor rapamycin increased the
Beclin1 and LC3 expression again compared to cell receiving RAGE antibody pretreatment.
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In idiopathic dilated cardiomyopathy, the prevalence of
autophagic cells are 40 times more than apoptotic cells
[19], suggesting importance of autophagic death in
heart function maintenance. Myocardial autophagy is
reported to contribute to post-burn cardiac dysfunction
in rat model and enhanced autophagy with Rapamycindecreased cardiac functon while inhibits autophagy with
3-MAprotects the cardiac function [35]. In this study, we
found that the AGEs induced autogphagy and contribute
to the impairment of cell viability. This finding suggests
that the pharmacological regulation of autophagy may be
an anther plausible strategy to prevent the progressive
heart function loss in high AGEs setting, e.g. DM patients.
Figure 5 Compared to control cells, compared to control cells, rapamycin along increased the autophagy level indicated by the
number of average number of LC3-labeled puncta per cell (Figure 5). RAGE antibody pretreatment markedly reduced the formation of
autolysosome in cultured cardiomyocytes, which can be induced again by the addition of rapamycin.
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the signal transduction pathway under which AGEs in-
duced autphagy in cardiomyocytes. The effect of AGEs on
PI3K/Akt/mTOR pathway is quiet controversial. AGEs
stimulated phosphorylation of Akt in macrophages [36]
and triggers activation of the PI3K pathways in mesangialFigure 6 Cardiomyocyte viability after the Inhibition of RAGE and PI3
AGEs treatment dramatically reduced the cell viability, but rapamycin along
antibody can rescue cell viability induced by AGEs treatment; however, thiscells [37]. In contrast, AGEs upregulate the RAGE expres-
sion, but downregulate the Akt activity late endothelial
progenitor cells [38]. In rat vascular smooth muscle cells,
AGEs treatment inhibits the phosphorylation of Akt and
mTOR [23]. In the present study, we showed that AGEs
induced the autophagy in cardiomyoctyes via suppressingK/Akt/mTOR pathway on cell viability. Compared to control cells,
did not significantly change the cell viability. Inhibition of RAGE by its
beneficial effect was abolished by additional rapamycin treatment.
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this modulation of this pathway led to functional changes
in cell viability, suggesting that this pathway may be the
pharmacological target in the regulation of autophagy in
cardiomyocytes.
Limitations should be addressed in current study. Firstly,
we only studied the effect of AGEs perfusion on cardio-
myocyte autophagy and did not assess its effect on cardio-
myocyte apoptosis. We did not compare the contribution
of cardiomycyte autophagy and apoptosis in heat function
loss in this study. Secondly, it should be pointed out that
the PI3K/Akt/ mTOR signal pathway is not the only regu-
lator of also modulate the autophagy. We did not study
the other signal pathway in this study.
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